Goldman Sachs upgrades Rocket Pharmaceuticals stock rating on Danon disease drug progress
Covered in this story
Analyst targets on Goldman Sachs
- UBS: $893 → $1.01k by Oct 2027 · neutral via marketbeat.com
- BMO Capital Markets: $1.15k → $1.19k by Jul 2027 · Market Perform via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $GS yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Goldman Sachs →Dalsna Finance is currently tracking 60 stories mentioning Goldman Sachs, the earliest published 22 May 2026.
Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.